Syndeio, a CNS biotechnology startup, has secured $90 million in funding to develop predictive pharmacology approaches that optimize synaptic transmission through precise dosing strategies. The company results from the combination of two biotechs focused on restoring neural circuitry and regulatory mechanisms. Synaptic modulation represents a critical frontier in treating neurological disorders, aiming to fine-tune communication pathways and improve functional outcomes for patients.